Klaria Pharma Holding AB (publ.) (FRA:6FN)

Market Cap	20.08M +42.7%
Revenue (ttm)	830.24K +299.7%
Net Income	-3.59M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0718
Previous Close	0.0718
Day's Range	0.0718 - 0.0718
52-Week Range	0.0308 - 0.1185
Beta	n/a
RSI	47.72
Earnings Date	Feb 20, 2026

About FRA:6FN

Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; and Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. The company is also involved in commercialization and sale of...

• Industry: Pharmaceutical Preparations
• Founded: 2014
• Employees: 4
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6FN

Financial Performance

In 2025, FRA:6FN's revenue was 8.99 million, an increase of 299.69% compared to the previous year's 2.25 million. Losses were -38.89 million, -18.56% less than in 2024.

Financial numbers in SEK